ATE476992T1 - Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper - Google Patents

Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper

Info

Publication number
ATE476992T1
ATE476992T1 AT04800068T AT04800068T ATE476992T1 AT E476992 T1 ATE476992 T1 AT E476992T1 AT 04800068 T AT04800068 T AT 04800068T AT 04800068 T AT04800068 T AT 04800068T AT E476992 T1 ATE476992 T1 AT E476992T1
Authority
AT
Austria
Prior art keywords
hgf
neutralizing antibodies
antibodies binding
neutralizable epitope
binding
Prior art date
Application number
AT04800068T
Other languages
English (en)
Inventor
Junho Chung
Youngmi Hur
Original Assignee
Nat Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Cancer Ct filed Critical Nat Cancer Ct
Application granted granted Critical
Publication of ATE476992T1 publication Critical patent/ATE476992T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
AT04800068T 2003-11-11 2004-11-09 Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper ATE476992T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030079482A KR100556660B1 (ko) 2003-11-11 2003-11-11 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
PCT/KR2004/002888 WO2005044848A1 (en) 2003-11-11 2004-11-09 Neutralizable epitope of hgf and neutralizing antibody binding to the same

Publications (1)

Publication Number Publication Date
ATE476992T1 true ATE476992T1 (de) 2010-08-15

Family

ID=36660022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04800068T ATE476992T1 (de) 2003-11-11 2004-11-09 Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper

Country Status (11)

Country Link
US (2) US7408043B2 (de)
EP (1) EP1694700B1 (de)
JP (1) JP4446393B2 (de)
KR (1) KR100556660B1 (de)
CN (2) CN101434654A (de)
AT (1) ATE476992T1 (de)
AU (1) AU2004287743B2 (de)
DE (1) DE602004028651D1 (de)
ES (1) ES2346887T3 (de)
HK (1) HK1098769A1 (de)
WO (1) WO2005044848A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
AU2006305119B2 (en) 2005-10-21 2012-12-20 Chugai Seiyaku Kabushiki Kaisha Agents for treating cardiopathy
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) * 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
US8691224B2 (en) * 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
CN101370521A (zh) 2006-01-27 2009-02-18 学校法人庆应义塾 伴有脉络膜血管生成的疾病的治疗药
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CA2648644C (en) 2006-04-07 2016-01-05 Osaka University Muscle regeneration promoter
MX2008015138A (es) 2006-06-02 2009-01-28 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch).
AR061171A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch)
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN101646459B (zh) 2007-01-23 2014-02-12 国立大学法人信州大学 慢性排斥反应抑制剂
US20100311767A1 (en) * 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP3511342B1 (de) 2010-03-10 2024-01-17 Genmab A/S Monoklonale antikörper gegen c-met
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
EP2402370A1 (de) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Neuartiger Antikörper zur Diagnose und/oder Prognose von Krebs
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
US8637027B2 (en) * 2010-11-03 2014-01-28 Argen-X B.V. Anti c-Met antibodies
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
CN104321342B (zh) 2012-03-15 2017-12-22 首尔大学校产学协力团 Gremlin‑1抗体
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9481725B2 (en) * 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
EP3037525B1 (de) 2013-09-30 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung eines antigenbindenden moleküls unter verwendung von modifizierten helferphagen
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
WO2016060297A1 (ko) * 2014-10-16 2016-04-21 주식회사 파멥신 VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
EP3698808A4 (de) 2017-10-20 2021-07-14 Hyogo College Of Medicine Anti-il-6 rezeptorantikörper enthaltende medizinische zusammensetzung zur verhinderung von postoperativer adhäsion
WO2023039612A1 (en) * 2021-09-13 2023-03-16 The Board Of Regents Of The University Of Texas System Trem2 antigen binding proteins and uses thereof
WO2023056527A1 (en) * 2021-10-07 2023-04-13 The University Of Queensland Proteinaceous molecules and uses therefor
KR20230148435A (ko) * 2022-04-14 2023-10-25 주식회사 셀랩메드 키메릭 항원 수용체 및 hgf 결합 억제 물질의 조합 요법
KR20230148433A (ko) 2022-04-14 2023-10-25 주식회사 셀랩메드 키메릭 항원 수용체 및 hgf 중화항체의 조합 요법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241574A (zh) * 1998-07-02 2000-01-19 中国人民解放军第四军医大学 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体

Also Published As

Publication number Publication date
EP1694700A1 (de) 2006-08-30
US20070036789A1 (en) 2007-02-15
AU2004287743B2 (en) 2008-10-09
AU2004287743A1 (en) 2005-05-19
KR100556660B1 (ko) 2006-03-10
CN100447158C (zh) 2008-12-31
EP1694700A4 (de) 2007-10-31
JP2007532097A (ja) 2007-11-15
ES2346887T3 (es) 2010-10-21
WO2005044848A1 (en) 2005-05-19
US20090023894A1 (en) 2009-01-22
DE602004028651D1 (de) 2010-09-23
KR20050045419A (ko) 2005-05-17
EP1694700B1 (de) 2010-08-11
US7408043B2 (en) 2008-08-05
JP4446393B2 (ja) 2010-04-07
CN101434654A (zh) 2009-05-20
CN1878790A (zh) 2006-12-13
HK1098769A1 (en) 2007-07-27

Similar Documents

Publication Publication Date Title
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
NO2017032I1 (no) bezlotoksumab
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
LU92710I2 (fr) Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
PA8645301A1 (es) Anticuerpo anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
NZ597767A (en) Antibodies to IL-6 and use thereof
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
SG166090A1 (en) Il-13 binding agents
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
NZ594682A (en) Fully human antibodies specific to cadm1
DE60235588D1 (de) Monoklonales Antikörper gegen das HCV Kernantigen
ATE473279T1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
MX2007013108A (es) Reactivos que enlazan ccx-ckr2.
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs
ATE294148T1 (de) Chromatreduziertes hydraulisches bindemittel
TR201900355T4 (tr) Anti-ctla-4 antikor kompozisyonları.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1694700

Country of ref document: EP